#,ama,title,journal,year,volume,issue,pages,doi,pmid,authors
1,"Clive A, Bhatnagar R, Preston NJ. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016;5:10529.",Interventions for the management of malignant pleural effusions: a network meta-analysis,Cochrane Database Syst Rev,2016,,5,10529,,,Clive A; Bhatnagar R; Preston NJ
2,"Roberts ME, Neville E, Berrisford RG. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(2).",Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010,Thorax,2010,65,2,,,,Roberts ME; Neville E; Berrisford RG
3,"Davies HE, Mishra EK, Kahan BC. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307.",Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial,JAMA,2012,307,,,,,Davies HE; Mishra EK; Kahan BC
4,"Rahman NM, Pepperell J, Rehal S. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA. 2015;314.",Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial,JAMA,2015,314,,,,,Rahman NM; Pepperell J; Rehal S
5,"Rintoul RC, Ritchie AJ, Edwards JG. A multi-centre randomised controlled trial of video assisted thoracoscopic pleurectomy versus talc pleurodesis in malignant pleural mesothelioma. J Thorac Oncol. 2013;8.",A multi-centre randomised controlled trial of video assisted thoracoscopic pleurectomy versus talc pleurodesis in malignant pleural mesothelioma,J Thorac Oncol,2013,8,,,,,Rintoul RC; Ritchie AJ; Edwards JG
6,"Bucknor A, Harrison-Phipps K, Davies T. Is silver nitrate an effective means of pleurodesis?. Interact Cardiovasc Thorac Surg. 2015;21.",Is silver nitrate an effective means of pleurodesis?,Interact Cardiovasc Thorac Surg,2015,21,,,,,Bucknor A; Harrison-Phipps K; Davies T
7,"Da Silveira Paschoalini M, Vargas FS, Marchi E. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest. 2005;128.",Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions,Chest,2005,128,,,,,Da Silveira Paschoalini M; Vargas FS; Marchi E
8,"Menna C, Andreetti C, Ibrahim M. The effect of silver nitrate pleurodesis after a failed thoracoscopic talc poudrage. Biomed Res Int. 2013;2013:295890.",The effect of silver nitrate pleurodesis after a failed thoracoscopic talc poudrage,Biomed Res Int,2013,2013,,295890,,,Menna C; Andreetti C; Ibrahim M
9,"Tan C, Sedrakyan A, Browne J. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29.",The evidence on the effectiveness of management for malignant pleural effusion: a systematic review,Eur J Cardiothorac Surg,2006,29,,,,,Tan C; Sedrakyan A; Browne J
10,"Mummadi SK, Kumbam A, Hahn PY. Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis. Research. 1000;3:254.",Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis,Research,1000,3,,254,,,Mummadi SK; Kumbam A; Hahn PY
11,"Dresler CM, Olak J, Herndon JE. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127.",Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion,Chest,2005,127,,,,,Dresler CM; Olak J; Herndon JE
12,"Yim AP, Chan AT, Lee TW. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg. 1996;62.",Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion,Ann Thorac Surg,1996,62,,,,,Yim AP; Chan AT; Lee TW
13,"Terra RM, Junqueira J, Teixeira LR. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis. Chest. 2009;136.",Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis,Chest,2009,136,,,,,Terra RM; Junqueira J; Teixeira LR
14,"Benkó I, Molnár TF, Horváth OP. Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery. Acta Chir Hung. 1999;38.",Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery,Acta Chir Hung,1999,38,,,,,Benkó I; Molnár TF; Horváth OP
15,"Debeljak A, Kecelj P, Triller N. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON. 2006;11.",Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions,J BUON,2006,11,,,,,Debeljak A; Kecelj P; Triller N
16,"Stefani A, Natali P, Casali C. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg. 2006;30.",Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study,Eur J Cardiothorac Surg,2006,30,,,,,Stefani A; Natali P; Casali C
17,"Luh SP, Chen CY, Tzao CY. Malignant pleural effusion treatment outcomes: pleurodesis via video-assisted thoracic surgery (VATS) versus tube thoracostomy. Thorac Cardiovasc Surg. 2006;54.",Malignant pleural effusion treatment outcomes: pleurodesis via video-assisted thoracic surgery (VATS) versus tube thoracostomy,Thorac Cardiovasc Surg,2006,54,,,,,Luh SP; Chen CY; Tzao CY
18,"Jancovici R, Lang-Lazdunski L, Pons F. Complications of video-assisted thoracic surgery: a five-year experience. Ann Thorac Surg. 1996;61.",Complications of video-assisted thoracic surgery: a five-year experience,Ann Thorac Surg,1996,61,,,,,Jancovici R; Lang-Lazdunski L; Pons F
19,"Cardillo G, Facciolo F, Carbone L. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg. 2002;21.",Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions,Eur J Cardiothorac Surg,2002,21,,,,,Cardillo G; Facciolo F; Carbone L
20,"Canto A, Guijarro R, Arnau A. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions. Thorac Cardiovasc Surg. 1997;45.",Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions,Thorac Cardiovasc Surg,1997,45,,,,,Canto A; Guijarro R; Arnau A
21,"Steger V, Mika U, Toomes H. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg. 2007;83.",Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses,Ann Thorac Surg,2007,83,,,,,Steger V; Mika U; Toomes H
22,"Janssen JP, Collier G, Astoul P. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet. 2007;369.",Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study,Lancet,2007,369,,,,,Janssen JP; Collier G; Astoul P
23,"De Campos JR, Vargas FS, De Campos Werebe E. Thoracoscopy talc poudrage: a 15-year experience. Chest. 2001;119.",Thoracoscopy talc poudrage: a 15-year experience,Chest,2001,119,,,,,De Campos JR; Vargas FS; De Campos Werebe E
24,"Barbetakis N, Asteriou C, Papadopoulou F. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg. 2010;5:27.",Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases,J Cardiothorac Surg,2010,5,,27,,,Barbetakis N; Asteriou C; Papadopoulou F
25,"Viallat JR, Rey F, Astoul P. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest. 1996;110.",Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases,Chest,1996,110,,,,,Viallat JR; Rey F; Astoul P
26,"Koledin M, Duric D, Milovancev A. Pleural effusions of malignant etiology: diagnostics, treatment and quality of life. Arch Oncol. 2001;9.","Pleural effusions of malignant etiology: diagnostics, treatment and quality of life",Arch Oncol,2001,9,,,,,Koledin M; Duric D; Milovancev A
27,"Agrawal A, Tandon R, Lalit S. Clinico-pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P. with special reference to lung cancer. Lung India. 2015;32.",Clinico-pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P. with special reference to lung cancer,Lung India,2015,32,,,,,Agrawal A; Tandon R; Lalit S
28,"Arapis K, Caliandro R, Stern JB. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc. 2006;20.",Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients,Surg Endosc,2006,20,,,,,Arapis K; Caliandro R; Stern JB
29,"Bal S, Hasan SS. Thoracoscopic management of malignant pleural effusion. Int Surg. 1993;78.",Thoracoscopic management of malignant pleural effusion,Int Surg,1993,78,,,,,Bal S; Hasan SS
30,"Trotter D, Aly A, Siu L. Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience. Heart Lung Circ. 2005;14.",Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience,Heart Lung Circ,2005,14,,,,,Trotter D; Aly A; Siu L
31,"Sanchez-Armengol A, Rodriguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Chest. 1993;104.","Survival and talc pleurodesis in metastatic pleural carcinoma, revisited",Chest,1993,104,,,,,Sanchez-Armengol A; Rodriguez-Panadero F
32,"Schniewind B, Rose T, Woltmann N. Clinical outcomes and health-related quality of life after thoracoscopic talc pleurodesis. J Palliat Med. 2012;15.",Clinical outcomes and health-related quality of life after thoracoscopic talc pleurodesis,J Palliat Med,2012,15,,,,,Schniewind B; Rose T; Woltmann N
33,"Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest. 2005;128.",Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions,Chest,2005,128,,,,,Kolschmann S; Ballin A; Gillissen A
34,"Schulze M, Boehle AS, Kurdow R. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg. 2001;71.",Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients,Ann Thorac Surg,2001,71,,,,,Schulze M; Boehle AS; Kurdow R
35,"Clementsen P, Evald T, Grode G. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med. 1998;92.",Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study,Respir Med,1998,92,,,,,Clementsen P; Evald T; Grode G
36,"Mager H, Maesen B, Verzijlbergen F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer. 2002;36.",Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis,Lung Cancer,2002,36,,,,,Mager H; Maesen B; Verzijlbergen F
37,"Arellano-Orden E, Romero-Falcon A, Juan JM. Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis. Respiration. 2013;86.",Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis,Respiration,2013,86,,,,,Arellano-Orden E; Romero-Falcon A; Juan JM
38,"Habal P, Omran N, Jankovicova K. Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159.",Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment,Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2015,159,,,,,Habal P; Omran N; Jankovicova K
39,"Rodriguez-Panadero F, Segado A, Juan M, J. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med. 1995;151.",Failure of talc pleurodesis is associated with increased pleural fibrinolysis,Am J Respir Crit Care Med,1995,151,,,,,Rodriguez-Panadero F; Segado A; Juan M; J
40,"Korsic MB, Badovinac S, Cucevic B. Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study. Wien Klin Wochenschr. 2015;127.",Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study,Wien Klin Wochenschr,2015,127,,,,,Korsic MB; Badovinac S; Cucevic B
41,"Yoon DW, Cho JH, Choi YS. Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion. Thorac Cancer. 2016;7.",Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion,Thorac Cancer,2016,7,,,,,Yoon DW; Cho JH; Choi YS
42,"Friedel G, Linder A, Toomes H. Video-assisted thoracoscopic pleurectomy as therapy for recurring malignant pleural effusion. Minim Invasive Ther. 1994;3.",Video-assisted thoracoscopic pleurectomy as therapy for recurring malignant pleural effusion,Minim Invasive Ther,1994,3,,,,,Friedel G; Linder A; Toomes H
43,"Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest. 1995;107.",Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion,Chest,1995,107,,,,,Waller DA; Morritt GN; Forty J
44,"Ohta Y, Oda M, Shimizu J. Multimodality treatment including parietal pleurectomy as a possible therapeutic procedure for malignant pleural effusion. Surg Technol Int. 2007;16. doi:10.1183/13993003.00349-2018.",Multimodality treatment including parietal pleurectomy as a possible therapeutic procedure for malignant pleural effusion,Surg Technol Int,2007,16,,,10.1183/13993003.00349-2018,,Ohta Y; Oda M; Shimizu J
45,"Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J Cardiothorac Surg. 2004;26.",Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma,Eur J Cardiothorac Surg,2004,26,,,,,Crnjac A; Sok M; Kamenik M
46,"Hojski A, Leitgeb M, Crnjac A. Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study. Radiol Oncol. 2015;49.",Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study,Radiol Oncol,2015,49,,,,,Hojski A; Leitgeb M; Crnjac A
47,"Gu LJ, Wang WJ. non-small cell lung cancer. Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to. None;None.",non-small cell lung cancer,Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to,,,,,,,Gu LJ; Wang WJ
48,"Fang N, Ke Y, Xue D. Bao. Bao. 2006;26.",Bao,Bao,2006,26,,,,,Fang N; Ke Y; Xue D
49,"Bernard A, De Dompsure Régis B, Hagry O. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg. 2002;74.",Early and late mortality after pleurodesis for malignant pleural effusion,Ann Thorac Surg,2002,74,,,,,Bernard A; De Dompsure Régis B; Hagry O
50,"Mineo TC, Federico FS, T. Quality of life and outcomes after nonintubated versus intubated video-thoracoscopic pleurodesis for malignant pleural effusion: comparison by a case-matched study. J Palliat Med. 2014;17.",Quality of life and outcomes after nonintubated versus intubated video-thoracoscopic pleurodesis for malignant pleural effusion: comparison by a case-matched study,J Palliat Med,2014,17,,,,,Mineo TC; Federico FS; T
51,"Ost DE, Jimenez CA, Lei X. Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest. 2014;145.",Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters,Chest,2014,145,,,,,Ost DE; Jimenez CA; Lei X
52,"Warren WH, Kalimi R, Khodadadian LM. Management of malignant pleural effusions using the Pleur x catheter. Ann Thorac Surg. 2008;85.",Management of malignant pleural effusions using the Pleur x catheter,Ann Thorac Surg,2008,85,,,,,Warren WH; Kalimi R; Khodadadian LM
53,"Tremblay AM, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129.",Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion,Chest,2006,129,,,,,Tremblay AM; Michaud G
54,"Sabur NF, Chee A, Stather DR. The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration. 2013;85.",The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions,Respiration,2013,85,,,,,Sabur NF; Chee A; Stather DR
55,"Gilbert CR, Lee HJ, Skalski JH. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study. Chest. 2015;148.",The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study,Chest,2015,148,,,,,Gilbert CR; Lee HJ; Skalski JH
56,"Bazerbashi S, Villaquiran J, Awan MY. Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience. Ann Surg Oncol. 2009;16.",Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience,Ann Surg Oncol,2009,16,,,,,Bazerbashi S; Villaquiran J; Awan MY
57,"Van Meter M, Mckee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26.",Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review,J Gen Intern Med,2011,26,,,,,Van Meter M; Mckee KY; Kohlwes RJ
58,"Putnam JB, Light RW, Rodriguez RM. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86.",A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions,Cancer,1999,86,,,,,Putnam JB; Light RW; Rodriguez RM
59,"Thomas R, Fysh EH, Smith NA. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA. 2017;318.",Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial,JAMA,2017,318,,,,,Thomas R; Fysh EH; Smith NA
60,"Demmy TL, Gu L, Burkhalter JE. Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Canc Netw. 2012;10.",Optimal management of malignant pleural effusions (results of CALGB 30102),J Natl Compr Canc Netw,2012,10,,,,,Demmy TL; Gu L; Burkhalter JE
61,"Hunt BM, Farivar AS, Vallières E. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg. 2012;94.",Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions,Ann Thorac Surg,2012,94,,,,,Hunt BM; Farivar AS; Vallières E
62,"Fysh E, Waterer GW, Kendall PA. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012;142.",Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion,Chest,2012,142,,,,,Fysh E; Waterer GW; Kendall PA
63,"Bell D, Wright G. A retrospective review of the palliative surgical management of malignant pleural effusions. BMJ Support Palliat Care. 2014;4.",A retrospective review of the palliative surgical management of malignant pleural effusions,BMJ Support Palliat Care,2014,4,,,,,Bell D; Wright G
64,"Walker S, Zubrinic M, Massey CZ. A prospective study of patient-centred outcomes in the management of malignant pleural effusions. Int J Palliat Nurs. 2016;22.",A prospective study of patient-centred outcomes in the management of malignant pleural effusions,Int J Palliat Nurs,2016,22,,,,,Walker S; Zubrinic M; Massey CZ
65,"Wahidi MM, Reddy C, Yarmus L. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. Am J Respir Crit Care Med. 2017;195.",Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial,Am J Respir Crit Care Med,2017,195,,,,,Wahidi MM; Reddy C; Yarmus L
66,"Schneider T, Reimer P, Storz K. Recurrent pleural effusion: who benefits from a tunneled pleural catheter?. Thorac Cardiovasc Surg. 2009;57.",Recurrent pleural effusion: who benefits from a tunneled pleural catheter?,Thorac Cardiovasc Surg,2009,57,,,,,Schneider T; Reimer P; Storz K
67,"Boujaoude Z, Bartter T, Abboud M. Pleuroscopic pleurodesis combined with tunneled pleural catheter for management of malignant pleural effusion: a prospective observational study. J Bronchology Interv Pulmonol. 2015;22.",Pleuroscopic pleurodesis combined with tunneled pleural catheter for management of malignant pleural effusion: a prospective observational study,J Bronchology Interv Pulmonol,2015,22,,,,,Boujaoude Z; Bartter T; Abboud M
68,"Reddy C, Ernst A, Lamb C. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139.",Rapid pleurodesis for malignant pleural effusions: a pilot study,Chest,2011,139,,,,,Reddy C; Ernst A; Lamb C
69,"Freeman RK, Anthony JA, Raja SM. A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy. Ann Thorac Surg. 2013;96.",A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy,Ann Thorac Surg,2013,96,,,,,Freeman RK; Anthony JA; Raja SM
70,"Bhatnagar R, Laskawiec-Szkonter M, Piotrowska H. Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open. 2014;4:e007045.",Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial,BMJ Open,2014,4,,e007045,,,Bhatnagar R; Laskawiec-Szkonter M; Piotrowska H
71,"Rintoul RC, Ritchie AJ, Edwards JG. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384.","Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial",Lancet,2014,384,,,,,Rintoul RC; Ritchie AJ; Edwards JG
72,"Huggins JT, Doelken P, Sahn SA. The unexpandable lung. Med Rep. 1000;2:77.",The unexpandable lung,Med Rep,1000,2,,77,,,Huggins JT; Doelken P; Sahn SA
73,Doelken P. Clinical implications of unexpandable lung due to pleural disease. Am J Med Sci. 2008;335.,Clinical implications of unexpandable lung due to pleural disease,Am J Med Sci,2008,335,,,,,Doelken P
74,"Lan R, Lo SK, Chuang M. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med. 1997;126.",Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion,Ann Intern Med,1997,126,,,,,Lan R; Lo SK; Chuang M
75,"Huggins JT, Doelken P. Pleural manometry. Clin Chest Med. 2006;27.",Pleural manometry,Clin Chest Med,2006,27,,,,,Huggins JT; Doelken P
76,Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med. 2007;13.,Therapeutic thoracentesis: the role of ultrasound and pleural manometry,Curr Opin Pulm Med,2007,13,,,,,Feller-Kopman D
77,"Boshuizen RC, Sinaasappel M, Vincent AD. Pleural pressure swing and lung expansion after malignant pleural effusion drainage: the benefits of high-temporal resolution pleural manometry. J Bronchology Interv Pulmonol. 2013;20.",Pleural pressure swing and lung expansion after malignant pleural effusion drainage: the benefits of high-temporal resolution pleural manometry,J Bronchology Interv Pulmonol,2013,20,,,,,Boshuizen RC; Sinaasappel M; Vincent AD
78,"Feller-Kopman D, Walkey A, Berkowitz D. The relationship of pleural pressure to symptom development during therapeutic thoracentesis. Chest. 2006;129.",The relationship of pleural pressure to symptom development during therapeutic thoracentesis,Chest,2006,129,,,,,Feller-Kopman D; Walkey A; Berkowitz D
79,"Salamonsen MR, Lo AK, Ng AC. Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage. Chest. 2014;146.",Novel use of pleural ultrasound can identify malignant entrapped lung prior to effusion drainage,Chest,2014,146,,,,,Salamonsen MR; Lo AK; Ng AC
80,"Zahid I, Routledge T, Bille A. What is the best treatment for malignant pleural effusions?. Interact Cardiovasc Thorac Surg. 2011;12.",What is the best treatment for malignant pleural effusions?,Interact Cardiovasc Thorac Surg,2011,12,,,,,Zahid I; Routledge T; Bille A
81,"Pien GW, Gant MJ, Washam CL. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest. 2001;119.",Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion,Chest,2001,119,,,,,Pien GW; Gant MJ; Washam CL
82,"Ohm C, Park D, Vogen M. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. Am Surg. 2003;69.",Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions,Am Surg,2003,69,,,,,Ohm C; Park D; Vogen M
83,"Qureshi RA, Collinson SL, Powell RJ. Management of malignant pleural effusion associated with trapped lung syndrome. Asian Cardiovasc Thorac Ann. 2008;16.",Management of malignant pleural effusion associated with trapped lung syndrome,Asian Cardiovasc Thorac Ann,2008,16,,,,,Qureshi RA; Collinson SL; Powell RJ
84,"Van Den Toorn LM, Schaap E, Surmont VF. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer. 2005;50.",Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter,Lung Cancer,2005,50,,,,,Van Den Toorn LM; Schaap E; Surmont VF
85,"Burgers JA, Olijve A, Baas P. Chronic indwelling pleural catheter for malignant pleural effusion in 25 patients. Ned Tijdschr Geneeskd. 2006;150.",Chronic indwelling pleural catheter for malignant pleural effusion in 25 patients,Ned Tijdschr Geneeskd,2006,150,,,,,Burgers JA; Olijve A; Baas P
86,"Efthymiou CA, Masudi T, Thorpe J. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters. Interact Cardiovasc Thorac Surg. 2009;9.",Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters,Interact Cardiovasc Thorac Surg,2009,9,,,,,Efthymiou CA; Masudi T; Thorpe J
87,"Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions: the complementary role of talc pleurodesis and pleuroperitoneal shunting. Cancer. 1995;75.",Management of recurrent malignant pleural effusions: the complementary role of talc pleurodesis and pleuroperitoneal shunting,Cancer,1995,75,,,,,Petrou M; Kaplan D; Goldstraw P
88,"Genc O, Petrou M, Ladas G. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg. 2000;18.",The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions,Eur J Cardiothorac Surg,2000,18,,,,,Genc O; Petrou M; Ladas G
89,"Yim AP, Ho JK, Lee TW. Thoracoscopic management of pleural effusions revisited. Aust N Z J Surg. 1995;65.",Thoracoscopic management of pleural effusions revisited,Aust N Z J Surg,1995,65,,,,,Yim AP; Ho JK; Lee TW
90,"Hsu LH, Soong TC, Feng AC. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients. J Thorac Oncol. 2006;1.",Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients,J Thorac Oncol,2006,1,,,,,Hsu LH; Soong TC; Feng AC
91,"Chung C, Chen C, Sheu J. Proinflammatory cytokines, transforming growth factor-β1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates. Chest. 2005;128.","Proinflammatory cytokines, transforming growth factor-β1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates",Chest,2005,128,,,,,Chung C; Chen C; Sheu J
92,"Sioris T, Sihvo E, Salo J. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol. 2009;35.",Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis,Eur J Surg Oncol,2009,35,,,,,Sioris T; Sihvo E; Salo J
93,"Bielsa S, Martin-Juan J, Porcel JM. Diagnostic and prognostic implications of pleural adhesions in malignant effusions. J Thorac Oncol. 2008;3.",Diagnostic and prognostic implications of pleural adhesions in malignant effusions,J Thorac Oncol,2008,3,,,,,Bielsa S; Martin-Juan J; Porcel JM
94,"Mason AC, Miller BH, Krasna MJ. Accuracy of CT for the detection of pleural adhesions: correlation with video-assisted thoracoscopic surgery. Chest. 1999;115.",Accuracy of CT for the detection of pleural adhesions: correlation with video-assisted thoracoscopic surgery,Chest,1999,115,,,,,Mason AC; Miller BH; Krasna MJ
95,"Cassanelli N, Caroli G, Dolci G. Accuracy of transthoracic ultrasound for the detection of pleural adhesions. Eur J Cardiothorac Surg. 2012;42.",Accuracy of transthoracic ultrasound for the detection of pleural adhesions,Eur J Cardiothorac Surg,2012,42,,,,,Cassanelli N; Caroli G; Dolci G
96,"Wei B, Wang T, Jiang F. Use of transthoracic ultrasound to predict pleural adhesions: a prospective blinded study. Thorac Cardiovasc Surg. 2012;60.",Use of transthoracic ultrasound to predict pleural adhesions: a prospective blinded study,Thorac Cardiovasc Surg,2012,60,,,,,Wei B; Wang T; Jiang F
97,"Medford AR, Agrawal S, Bennett JA. Thoracic ultrasound prior to medical thoracoscopy improves pleural access and predicts fibrous septation. Respirology. 2010;15.",Thoracic ultrasound prior to medical thoracoscopy improves pleural access and predicts fibrous septation,Respirology,2010,15,,,,,Medford AR; Agrawal S; Bennett JA
98,"Kohan JM, Poe RH, Israel RH. Value of chest ultrasonography versus decubitus roentgenography for thoracentesis. Am Rev Respir Dis. 1986;133.",Value of chest ultrasonography versus decubitus roentgenography for thoracentesis,Am Rev Respir Dis,1986,133,,,,,Kohan JM; Poe RH; Israel RH
99,"Havelock T, Teoh R, Laws D. Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65.",Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010,Thorax,2010,65,,,,,Havelock T; Teoh R; Laws D
100,"Silverman SG, Mueller PR, Saini S. Thoracic empyema: management with image-guided catheter drainage. Radiology. 1988;169.",Thoracic empyema: management with image-guided catheter drainage,Radiology,1988,169,,,,,Silverman SG; Mueller PR; Saini S
101,"Davies HE, Davies RJ, Davies CW. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(2).",Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010,Thorax,2010,65,2,,,,Davies HE; Davies RJ; Davies CW
102,"Vansonnenberg E, Nakamoto S, Mueller P. CT-and ultrasound-guided catheter drainage of empyemas after chest-tube failure. Radiology. 1984;151.",CT-and ultrasound-guided catheter drainage of empyemas after chest-tube failure,Radiology,1984,151,,,,,Vansonnenberg E; Nakamoto S; Mueller P
103,"Rahman NM, Maskell NA, West A. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365.",Intrapleural use of tissue plasminogen activator and DNase in pleural infection,N Engl J Med,2011,365,,,,,Rahman NM; Maskell NA; West A
104,"Balamugesh T, Christopher DJ, Rajesh T. Fibrinolysis of loculated pleural effusion in malignant mesothelioma. Singapore Med J. 2004;45.",Fibrinolysis of loculated pleural effusion in malignant mesothelioma,Singapore Med J,2004,45,,,,,Balamugesh T; Christopher DJ; Rajesh T
105,"Dixit R, Dixit K, Bansal R. Intrapleural streptokinase in multiloculated malignant pleural effusion. Indian J Chest Dis Allied Sci. 2004;46.",Intrapleural streptokinase in multiloculated malignant pleural effusion,Indian J Chest Dis Allied Sci,2004,46,,,,,Dixit R; Dixit K; Bansal R
106,"Maskell NA, Gleeson FV. Images in clinical medicine. Effect of intrapleural streptokinase on a loculated malignant pleural effusion. N Engl J Med. 2003;348:e4.",Images in clinical medicine. Effect of intrapleural streptokinase on a loculated malignant pleural effusion,N Engl J Med,2003,348,,e4,,,Maskell NA; Gleeson FV
107,"Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde JJ. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest. 1996;109.",Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial,Chest,1996,109,,,,,Jerjes-Sanchez C; Ramirez-Rivera A; Elizalde JJ
108,"Davies CW, Traill ZC, Gleeson FV. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest. 1999;115.",Intrapleural streptokinase in the management of malignant multiloculated pleural effusions,Chest,1999,115,,,,,Davies CW; Traill ZC; Gleeson FV
109,"Ben-Or S, Feins RH, Veeramachaneni NK. Effectiveness and risks associated with intrapleural alteplase by means of tube thoracostomy. Ann Thorac Surg. 2011;91.",Effectiveness and risks associated with intrapleural alteplase by means of tube thoracostomy,Ann Thorac Surg,2011,91,,,,,Ben-Or S; Feins RH; Veeramachaneni NK
110,"Gilkeson RC, Silverman P, Haaga JR. Using urokinase to treat malignant pleural effusions. AJR Am J Roentgenol. 1999;173.",Using urokinase to treat malignant pleural effusions,AJR Am J Roentgenol,1999,173,,,,,Gilkeson RC; Silverman P; Haaga JR
111,"Abu-Daff S, Maziak DE, Alshehab D. Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions-analysis of predictors for failure of therapy and bleeding: a cohort study. BMJ Open. 2013;3:e001887.",Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions-analysis of predictors for failure of therapy and bleeding: a cohort study,BMJ Open,2013,3,,e001887,,,Abu-Daff S; Maziak DE; Alshehab D
112,"Okur E, Baysungur V, Tezel C. Streptokinase for malignant pleural effusions: a randomized controlled study. Asian Cardiovasc Thorac Ann. 2011;19.",Streptokinase for malignant pleural effusions: a randomized controlled study,Asian Cardiovasc Thorac Ann,2011,19,,,,,Okur E; Baysungur V; Tezel C
113,"Saydam O, Karapinar K, Gokce M. The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study. Med Oncol. 2015;32:179.","The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study",Med Oncol,2015,32,,179,,,Saydam O; Karapinar K; Gokce M
114,"Mishra D, Dao C, Wills M. Randomised controlled trial of urokinase versus placebo for non-draining malignant pleural effusion. Am J Respir Crit Care Med. 2017;197.",Randomised controlled trial of urokinase versus placebo for non-draining malignant pleural effusion,Am J Respir Crit Care Med,2017,197,,,,,Mishra D; Dao C; Wills M
115,"Thomas R, Piccolo F, Miller D. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. Chest. 2015;148. doi:10.1183/13993003.00349-2018115.",Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study,Chest,2015,148,,,10.1183/13993003.00349-2018115,,Thomas R; Piccolo F; Miller D
116,"Antony VB, Loddenkemper R, Astoul P. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162:116.",Management of malignant pleural effusions,Am J Respir Crit Care Med,2000,162,,116,,,Antony VB; Loddenkemper R; Astoul P
117,"Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest. 2000;117:117.",Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions,Chest,2000,117,,117,,,Heffner JE; Nietert PJ; Barbieri C
118,"Abakay A, Komek H, Abakay O. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci. 2013;17:118.",Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma,Eur Rev Med Pharmacol Sci,2013,17,,118,,,Abakay A; Komek H; Abakay O
119,"Zamboni MM, Da Silva CT, Baretta R. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015;15:119.",Important prognostic factors for survival in patients with malignant pleural effusion,BMC Pulm Med,2015,15,,119,,,Zamboni MM; Da Silva CT; Baretta R
120,"Bielsa S, Salud A, Martínez M. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med. 2008;19:120.",Prognostic significance of pleural fluid data in patients with malignant effusion,Eur J Intern Med,2008,19,,120,,,Bielsa S; Salud A; Martínez M
121,"Fentiman IS, Millis R, Sexton S. Pleural effusion in breast cancer: a review of 105 cases. Cancer. 1981;47:121.",Pleural effusion in breast cancer: a review of 105 cases,Cancer,1981,47,,121,,,Fentiman IS; Millis R; Sexton S
122,"Anevlavis S, Kouliatsis G, Sotiriou I. Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration. 2014;87:122.",Prognostic factors in patients presenting with pleural effusion revealing malignancy,Respiration,2014,87,,122,,,Anevlavis S; Kouliatsis G; Sotiriou I
123,"Edge S, Byrd D, Compton C. American Joint Committee on Cancer. American Joint Committee on Cancer. 2009;None:123.",American Joint Committee on Cancer,American Joint Committee on Cancer,2009,,,123,,,Edge S; Byrd D; Compton C
124,"Rusch VW, Chansky K, Kindler HL. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol. 2016;11:124.",The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma,J Thorac Oncol,2016,11,,124,,,Rusch VW; Chansky K; Kindler HL
125,"Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32:125.","Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution",Eur J Cancer,1996,32,,125,,,Buccheri G; Ferrigno D; Tamburini M
126,"Hwang SS, Scott CB, Chang VT. Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress. Cancer Invest. 2004;22:126.","Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress",Cancer Invest,2004,22,,126,,,Hwang SS; Scott CB; Chang VT
127,"Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000;117:127.","Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease",Chest,2000,117,,127,,,Burrows CM; Mathews WC; Colt HG
128,"Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:128.",Toxicity and response criteria of the Eastern Cooperative Oncology Group,Am J Clin Oncol,1982,5,,128,,,Oken MM; Creech RH; Tormey DC
129,"Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents. 1949;None:129.",The clinical evaluation of chemotherapeutic agents in cancer,Evaluation of Chemotherapeutic Agents,1949,,,129,,,Karnofsky DA; Burchenal JH
130,"Martinez-Moragon E, Aparicio J, Sanchis J. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration. 1998;65:130.",Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases,Respiration,1998,65,,130,,,Martinez-Moragon E; Aparicio J; Sanchis J
131,"Jiménez D, Díaz G, Gil D. Etiology and prognostic significance of massive pleural effusions. Respir Med. 2005;99:131.",Etiology and prognostic significance of massive pleural effusions,Respir Med,2005,99,,131,,,Jiménez D; Díaz G; Gil D
132,"Sahn SA, Good JT. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med. 1988;108:132.","Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications",Ann Intern Med,1988,108,,132,,,Sahn SA; Good JT
133,"Sakr L, Maldonado F, Greillier L. Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications. J Thorac Oncol. 2011;6:133.",Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications,J Thorac Oncol,2011,6,,133,,,Sakr L; Maldonado F; Greillier L
134,"Wu S, Yu C, Tsai M. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 2013;41:134.",Survival of lung adenocarcinoma patients with malignant pleural effusion,Eur Respir J,2013,41,,134,,,Wu S; Yu C; Tsai M
135,"Soh J, Toyooka S, Aoe K. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006;119:135.",Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer,Int J Cancer,2006,119,,135,,,Soh J; Toyooka S; Aoe K
136,"Zalcman G, Mazieres J, Margery J. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2015;387:136.","Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial",Lancet,2015,387,,136,,,Zalcman G; Mazieres J; Margery J
137,"Gkiozos I, Tsagouli S, Charpidou A. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study. Anticancer Res. 2015;35:137.",Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study,Anticancer Res,2015,35,,137,,,Gkiozos I; Tsagouli S; Charpidou A
138,"Hsu IL, Su WC, Yan JJ. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:138.",Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control,Lung Cancer,2009,65,,138,,,Hsu IL; Su WC; Yan JJ
139,"Edwards JG, Abrams KR, Leverment JN. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:139.",Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems,Thorax,2000,55,,139,,,Edwards JG; Abrams KR; Leverment JN
140,"Edwards JG, Swinson DE, Jones JL. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest. 2003;124:140.",Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma,Chest,2003,124,,140,,,Edwards JG; Swinson DE; Jones JL
141,"Rutter M, Saunders B, Wilkinson K. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:141.",Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis,Gastroenterology,2004,126,,141,,,Rutter M; Saunders B; Wilkinson K
142,"Grivennikov SI, Greten FR, KM. Immunity, inflammation, and cancer. Cell. 2010;140:142.","Immunity, inflammation, and cancer",Cell,2010,140,,142,,,Grivennikov SI; Greten FR; KM
143,"Fearon K, Strasser F, Anker SD. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:143.",Definition and classification of cancer cachexia: an international consensus,Lancet Oncol,2011,12,,143,,,Fearon K; Strasser F; Anker SD
144,"Linton A, Van Zandwijk N, Reid G. Inflammation in malignant mesothelioma -friend or foe?. Ann Cardiothorac Surg. 2012;1:144.",Inflammation in malignant mesothelioma -friend or foe?,Ann Cardiothorac Surg,2012,1,,144,,,Linton A; Van Zandwijk N; Reid G
145,Mcmillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:145.,The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer,Cancer Treat Rev,2013,39,,145,,,Mcmillan DC
146,"Pinato DJ, Mauri FA, Ramakrishnan R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7:146.",Inflammation-based prognostic indices in malignant pleural mesothelioma,J Thorac Oncol,2012,7,,146,,,Pinato DJ; Mauri FA; Ramakrishnan R
147,"Forrest L, Mcmillan D, Mcardle C. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:147.",Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer,Br J Cancer,2003,89,,147,,,Forrest L; Mcmillan D; Mcardle C
148,"Sculier J, Chansky K, Crowley JJ. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol. 2008;3:148.",The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition,J Thorac Oncol,2008,3,,148,,,Sculier J; Chansky K; Crowley JJ
149,"Paesmans M, Sculier J, Libert P. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995;13:149.","Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party",J Clin Oncol,1995,13,,149,,,Paesmans M; Sculier J; Libert P
150,"Schmidt H, Bastholt L, Geertsen P. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:150.",Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model,Br J Cancer,2005,93,,150,,,Schmidt H; Bastholt L; Geertsen P
151,"Atzpodien J, Royston P, Wandert T. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:151.",Metastatic renal carcinoma comprehensive prognostic system,Br J Cancer,2003,88,,151,,,Atzpodien J; Royston P; Wandert T
152,"Lissoni P, Brivio F, Fumagalli L. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers. 2003;19:152.",Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors,Int J Biol Markers,2003,19,,152,,,Lissoni P; Brivio F; Fumagalli L
153,"Anraku M, Cunningham KS, Yun Z. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008;135:153.",Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma,J Thorac Cardiovasc Surg,2008,135,,153,,,Anraku M; Cunningham KS; Yun Z
154,"Yamada N, Oizumi S, Kikuchi E. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:154.",CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection,Cancer Immunol Immunother,2010,59,,154,,,Yamada N; Oizumi S; Kikuchi E
155,"Templeton AJ, Mcnamara MG, Šeruga B. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Canc Inst. 2014;106:155.",Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis,J Natl Canc Inst,2014,106,,155,,,Templeton AJ; Mcnamara MG; Šeruga B
156,"Kao S, Pavlakis N, Harvie R. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16:156.",High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy,Clin Cancer Res,2010,16,,156,,,Kao S; Pavlakis N; Harvie R
157,"Clive AO, Kahan BC, Hooper CE. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:157.",Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score,Thorax,2014,69,,157,,,Clive AO; Kahan BC; Hooper CE
158,"Linton A, Pavlakis N, Connell O, R. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111:158.",Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales,Br J Cancer,2014,111,,158,,,Linton A; Pavlakis N; Connell O; R
159,"Suzuki K, Kadota K, Sima CS. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother. 2011;60:159.",Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients,Cancer Immunol Immunother,2011,60,,159,,,Suzuki K; Kadota K; Sima CS
160,"Hooper CE, Lyburn ID, Searle J. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer. 2015;112:160.",The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication,Br J Cancer,2015,112,,160,,,Hooper CE; Lyburn ID; Searle J
161,"Lee YS, Nam HS, Lim JH. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients. BMC Cancer. 2017;17:161.",Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients,BMC Cancer,2017,17,,161,,,Lee YS; Nam HS; Lim JH
162,"Yao ZH, Tian GY, Yang SX. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma. Tumour Biol. 2014;35:162.",Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma,Tumour Biol,2014,35,,162,,,Yao ZH; Tian GY; Yang SX
163,"Yamagishi T, Fujimoto N, Nishi H. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90:163.",Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma,Lung Cancer,2015,90,,163,,,Yamagishi T; Fujimoto N; Nishi H
164,"Yao ZH, Tian GY, Wan YY. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2013;139:164.",Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma,J Cancer Res Clin Oncol,2013,139,,164,,,Yao ZH; Tian GY; Wan YY
165,"Borasio P, Berruti A, Bille A. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33:165.",Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients,Eur J Cardiothorac Surg,2008,33,,165,,,Borasio P; Berruti A; Bille A
166,"Christensen BC, Godleski JJ, Roelofs CR. Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect. 2008;116:166.",Asbestos burden predicts survival in pleural mesothelioma,Environ Health Perspect,2008,116,,166,,,Christensen BC; Godleski JJ; Roelofs CR
167,"Wolf AS, Richards WG, Tilleman TR. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg. 2010;90:167.",Characteristics of malignant pleural mesothelioma in women,Ann Thorac Surg,2010,90,,167,,,Wolf AS; Richards WG; Tilleman TR
168,"Vigneswaran WT, Kircheva DY, Ananthanarayanan V. Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma. Ann Thorac Surg. 2017;103:168.",Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma,Ann Thorac Surg,2017,103,,168,,,Vigneswaran WT; Kircheva DY; Ananthanarayanan V
169,"Baud M, Strano S, Dechartres A. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg. 2013;145:169.",Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis,J Thorac Cardiovasc Surg,2013,145,,169,,,Baud M; Strano S; Dechartres A
170,"Curran D, Sahmoud T, Therasse P. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:170.",Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience,J Clin Oncol,1998,16,,170,,,Curran D; Sahmoud T; Therasse P
171,"Francart J, Vaes E, Henrard S. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer. 2009;45:171.",A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials,Eur J Cancer,2009,45,,171,,,Francart J; Vaes E; Henrard S
172,"Kataoka Y, Yamamoto Y, Otsuki T. External validation of prognostic indices for overall survival of malignant pleural mesothelioma. Lung Cancer. None;113:172.",External validation of prognostic indices for overall survival of malignant pleural mesothelioma,Lung Cancer,,113,,172,,,Kataoka Y; Yamamoto Y; Otsuki T
173,"Bille A, Krug LM, Woo KM. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11:173.",Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma,J Thorac Oncol,2016,11,,173,,,Bille A; Krug LM; Woo KM
174,"Flores RM, Zakowski M, Venkatraman E. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:174.",Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center,J Thorac Oncol,2007,2,,174,,,Flores RM; Zakowski M; Venkatraman E
175,"Jennings CJ, Walsh PM, Deady S. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009. Cancer Epidemiol. 2014;38:175.",Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009,Cancer Epidemiol,2014,38,,175,,,Jennings CJ; Walsh PM; Deady S
176,"Montanaro F, Rosato R, Gangemi M. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer. 2009;124:176.",Survival of pleural malignant mesothelioma in Italy: a population-based study,Int J Cancer,2009,124,,176,,,Montanaro F; Rosato R; Gangemi M
177,"Taioli E, Wolf AS, Camacho-Rivera M. Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS One. 2015;10.","Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients",PLoS One,2015,10,,,,,Taioli E; Wolf AS; Camacho-Rivera M
178,"Rena O, Boldorini R, Papalia E. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma. Ann Thorac Surg. 2015;99:178.",Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma,Ann Thorac Surg,2015,99,,178,,,Rena O; Boldorini R; Papalia E
179,"Adel AM, Hafeez A, ZM, Sheikh E, ET. Malignant pleural mesothelioma: a retrospective analysis of clinicopathological and survival data. Thorac Cancer. 2011;2:179.",Malignant pleural mesothelioma: a retrospective analysis of clinicopathological and survival data,Thorac Cancer,2011,2,,179,,,Adel AM; Hafeez A; ZM; Sheikh E; ET
180,"Rahouma M, Aziz H, Ghaly G. Survival in good performance malignant pleural mesothelioma patients; prognostic factors and predictors of response. Asian Pac J Cancer Prev. 2017;18:180.",Survival in good performance malignant pleural mesothelioma patients; prognostic factors and predictors of response,Asian Pac J Cancer Prev,2017,18,,180,,,Rahouma M; Aziz H; Ghaly G
181,"Wang S, Ma K, Wang Q. The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database. Int J Surg. 2017;48:181.","The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database",Int J Surg,2017,48,,181,,,Wang S; Ma K; Wang Q
182,"Zhang A, Cao S, JS. Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. Neoplasma. 2017;64:182.",Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma,Neoplasma,2017,64,,182,,,Zhang A; Cao S; JS
183,"Kataoka Y, Yamamoto Y, Otsuki T. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index. Jpn J Clin Oncol. 2015;45:183.","A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index",Jpn J Clin Oncol,2015,45,,183,,,Kataoka Y; Yamamoto Y; Otsuki T
184,"Herndon JE, Green MR, Chahinian AP. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:184.",Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B,Chest,1998,113,,184,,,Herndon JE; Green MR; Chahinian AP
185,"Bottomley A, Coens C, Efficace F. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007;25:185.",Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma,J Clin Oncol,2007,25,,185,,,Bottomley A; Coens C; Efficace F
186,"Creaney J, Francis RJ, Dick IM. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2011;17:186.","Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden",Clin Cancer Res,2011,17,,186,,,Creaney J; Francis RJ; Dick IM
187,"Arnold DT, Fonseka D, Hamilton D, FW. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer. 2017;116:187.",Prognostication and monitoring of mesothelioma using biomarkers: a systematic review,Br J Cancer,2017,116,,187,,,Arnold DT; Fonseka D; Hamilton D; FW
188,"Hollevoet K, Nackaerts K, Gosselin R. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011;6:188.","Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma",J Thorac Oncol,2011,6,,188,,,Hollevoet K; Nackaerts K; Gosselin R
189,"Fennell DA, Parmar A, Shamash J. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 2005;23:189.",Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials,J Clin Oncol,2005,23,,189,,,Fennell DA; Parmar A; Shamash J
190,"Sandri A, Guerrera F, Roffinella M. Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma. J Thorac Dis. 2016;8:190.","Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma",J Thorac Dis,2016,8,,190,,,Sandri A; Guerrera F; Roffinella M
191,"Meniawy TM, Creaney J, Lake RA. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer. 2013;109:191.","Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma",Br J Cancer,2013,109,,191,,,Meniawy TM; Creaney J; Lake RA
192,"Wang S, Ma K, Chen Z. A nomogram to predict prognosis in malignant pleural mesothelioma. World J Surg. 2017;42:192.",A nomogram to predict prognosis in malignant pleural mesothelioma,World J Surg,2017,42,,192,,,Wang S; Ma K; Chen Z
193,"Brims FJ, Meniawy TM, Duffus I. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis. J Thorac Oncol. 2016;11:193.",A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis,J Thorac Oncol,2016,11,,193,,,Brims FJ; Meniawy TM; Duffus I
194,"Niho S, Kubota K, Yoh K. Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. J Thorac Oncol. 2008;3:194.",Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion,J Thorac Oncol,2008,3,,194,,,Niho S; Kubota K; Yoh K
195,"Herrstedt J, Clementsen P, Hansen OP. Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur J Cancer. 1992;28:196.",Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer,Eur J Cancer,1992,28,,196,,,Herrstedt J; Clementsen P; Hansen OP
196,"Adiguzel C, Bozkurt SU, Kaygusuz I. Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature. APMIS. 2009;117:197.",Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature,APMIS,2009,117,,197,,,Adiguzel C; Bozkurt SU; Kaygusuz I
197,"Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS. 2004;18:198.",Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review,AIDS Patient Care STDS,2004,18,,198,,,Waddington TW; Aboulafia DM
198,"Dabaja BS, Ha CS, Thomas DA. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002;94:199.",The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma,Cancer,2002,94,,199,,,Dabaja BS; Ha CS; Thomas DA
199,"Fujita A, Takabatake H, Tagaki S. Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support. Chest. 2001;119:200.","Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support",Chest,2001,119,,200,,,Fujita A; Takabatake H; Tagaki S
200,"Kitamura K, Kubota K, Ando M. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 2013;71:201.",Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion,Cancer Chemother Pharmacol,2013,71,,201,,,Kitamura K; Kubota K; Ando M
201,"Masago K, Fujimoto D, Fujita S. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol. 2015;3:202.",Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer,Mol Clin Oncol,2015,3,,202,,,Masago K; Fujimoto D; Fujita S
202,"Huang Z, Yan H, Chavan D. Effective treatment of a patient with stage IV ovarian cancer: a case report. Oncol Lett. 2018;15:203.",Effective treatment of a patient with stage IV ovarian cancer: a case report,Oncol Lett,2018,15,,203,,,Huang Z; Yan H; Chavan D
203,"Lin JB, Lai FC, Li X. Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation. J Drug Target. 2017;25:204.",Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation,J Drug Target,2017,25,,204,,,Lin JB; Lai FC; Li X
204,"Jiang T, Li A, Su C. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. Oncotarget. 2017;8:205.",Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients,Oncotarget,2017,8,,205,,,Jiang T; Li A; Su C
205,"Mori R, Fujimoto D, Ito M. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 2017;8:206.",Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature,Oncotarget,2017,8,,206,,,Mori R; Fujimoto D; Ito M
206,"Sebastian M, Kiewe P, Schuette W. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (removab) (anti-EpCAMxanti-CD3): results of a phase 1/2 study. J Immunother. 2009;32:207.",Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (removab) (anti-EpCAMxanti-CD3): results of a phase 1/2 study,J Immunother,2009,32,,207,,,Sebastian M; Kiewe P; Schuette W
207,"Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther. 2008;10:208.","Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer",Curr Opin Mol Ther,2008,10,,208,,,Shen J; Zhu Z
208,"Qi N, Li F, Li X. Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. Medicine. 2016;95:209.",Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion,Medicine,2016,95,,209,,,Qi N; Li F; Li X
209,"Du N, Li X, Li F. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 2013;29:210.",Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion,Oncol Rep,2013,29,,210,,,Du N; Li X; Li F
210,"Tamiya M, Tamiya A, Yamadori T. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol. 2013;30:211.",Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion,Med Oncol,2013,30,,211,,,Tamiya M; Tamiya A; Yamadori T
211,"Salyer WR, Eggleston JC, Erozan YS. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest. 1975;67:212.",Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura,Chest,1975,67,,212,,,Salyer WR; Eggleston JC; Erozan YS
212,"Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:213.",Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination,Mod Pathol,1991,4,,213,,,Nance KV; Shermer RW; Askin FB
213,"Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985;60:214.",Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases,Mayo Clin Proc,1985,60,,214,,,Prakash UB; Reiman HM
214,"Froudarakis ME, Plojoux J, Kaspi E. Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions. Clin Respir J. 2018;12:215.",Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions,Clin Respir J,2018,12,,215,,,Froudarakis ME; Plojoux J; Kaspi E
215,"Renshaw AA, Dean BR, Antman KH. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:216.",The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma,Chest,1997,111,,216,,,Renshaw AA; Dean BR; Antman KH
216,"Hooper C, Lee YC, Maskell N. BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65.",BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010,Thorax,2010,65,,,,,Hooper C; Lee YC; Maskell N
217,"Henderson DW, Reid G, Kao SC. Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66:218.","Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers",J Clin Pathol,2013,66,,218,,,Henderson DW; Reid G; Kao SC
218,"Segal A, Sterrett GF, Frost FA. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology. 2013;45:219.",A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit,Pathology,2013,45,,219,,,Segal A; Sterrett GF; Frost FA
219,"Rossi ED, Bizzarro T, Schmitt F. The role of liquid-based cytology and ancillary techniques in pleural and pericardic effusions: an institutional experience. Cancer Cytopathol. 2015;123:220.",The role of liquid-based cytology and ancillary techniques in pleural and pericardic effusions: an institutional experience,Cancer Cytopathol,2015,123,,220,,,Rossi ED; Bizzarro T; Schmitt F
220,"Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):221.","Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines",Chest,2013,143,5,221,,,Rivera MP; Mehta AC; Wahidi MM
221,"Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994;7:222.",The value of multiple fluid specimens in the cytological diagnosis of malignancy,Mod Pathol,1994,7,,222,,,Garcia LW; Ducatman BS; Wang HH
222,"Rakha EA, Patil S, Abdulla K. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:223.",The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma,Diagn Cytopathol,2010,38,,223,,,Rakha EA; Patil S; Abdulla K
223,"Pinelli V, Laroumagne S, Sakr L. Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma. J Thorac Oncol. 2012;7:224.",Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma,J Thorac Oncol,2012,7,,224,,,Pinelli V; Laroumagne S; Sakr L
224,"Abouzgheib W, Bartter T, Dagher H. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009;135:225.",A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion,Chest,2009,135,,225,,,Abouzgheib W; Bartter T; Dagher H
225,"Thomas SC, Davidson LR, Mckean ME. An investigation of adequate volume for the diagnosis of malignancy in pleural fluids. Cytopathology. 2011;22:226.",An investigation of adequate volume for the diagnosis of malignancy in pleural fluids,Cytopathology,2011,22,,226,,,Thomas SC; Davidson LR; Mckean ME
226,"Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases. Cancer Cytopathol. 2014;122:227.",A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases,Cancer Cytopathol,2014,122,,227,,,Rooper LM; Ali SZ; Olson MT
227,"Swiderek J, Morcos S, Donthireddy V. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010;137:228.",Prospective study to determine the volume of pleural fluid required to diagnose malignancy,Chest,2010,137,,228,,,Swiderek J; Morcos S; Donthireddy V
228,"Porcel JM, Quiros M, Gatius S. Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions. Rev Clin Esp. 2017;217:229.",Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions,Rev Clin Esp,2017,217,,229,,,Porcel JM; Quiros M; Gatius S
229,"Dekker A, Bupp PA. Cytology of serous effusions: an investigation into the usefulness of cell blocks versus smears. Am J Clin Pathol. 1978;70:230.",Cytology of serous effusions: an investigation into the usefulness of cell blocks versus smears,Am J Clin Pathol,1978,70,,230,,,Dekker A; Bupp PA
230,"Galateau-Salle F, Churg A, Roggli V. The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol. 2016;11:231.",The 2015 World Health Organization Classification of Tumors of the Pleura: advances since the 2004 classification,J Thorac Oncol,2016,11,,231,,,Galateau-Salle F; Churg A; Roggli V
231,"Husain AN, Colby T, Ordonez N. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137:232.",Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group,Arch Pathol Lab Med,2013,137,,232,,,Husain AN; Colby T; Ordonez N
232,"Husain AN, Colby TV, Ordonez NG. Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2017;142:233.",Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group,Arch Pathol Lab Med,2017,142,,233,,,Husain AN; Colby TV; Ordonez NG
233,"Karpathiou G, Stefanou D, Froudarakis ME. Pleural neoplastic pathology. Respir Med. 2015;109:234.",Pleural neoplastic pathology,Respir Med,2015,109,,234,,,Karpathiou G; Stefanou D; Froudarakis ME
234,"Yang Y, Liu YL, Shi HZ. Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis. Respiration. 2017;94:235.",Diagnostic accuracy of combinations of tumor markers for malignant pleural effusion: an updated meta-analysis,Respiration,2017,94,,235,,,Yang Y; Liu YL; Shi HZ
235,"Katz RL, Raval P, Manning JT. A morphologic, immunologic, and cytometric approach to the classification of non-Hodgkin's lymphoma in effusions. Diagn Cytopathol. 1987;3:236.","A morphologic, immunologic, and cytometric approach to the classification of non-Hodgkin's lymphoma in effusions",Diagn Cytopathol,1987,3,,236,,,Katz RL; Raval P; Manning JT
236,"Simsir A, Fetsch P, Stetler-Stevenson M. Immunophenotypic analysis of non-Hodgkin's lymphomas in cytologic specimens: a correlative study of immunocytochemical and flow cytometric techniques. Diagn Cytopathol. 1999;20:237.",Immunophenotypic analysis of non-Hodgkin's lymphomas in cytologic specimens: a correlative study of immunocytochemical and flow cytometric techniques,Diagn Cytopathol,1999,20,,237,,,Simsir A; Fetsch P; Stetler-Stevenson M
237,"Pillai V, Cibas ES, Dorfman DM. A simplified flow cytometric immunophenotyping procedure for the diagnosis of effusions caused by epithelial malignancies. Am J Clin Pathol. 2013;139:238.",A simplified flow cytometric immunophenotyping procedure for the diagnosis of effusions caused by epithelial malignancies,Am J Clin Pathol,2013,139,,238,,,Pillai V; Cibas ES; Dorfman DM
238,"Davidson B, Dong HP, Berner A. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Am J Clin Pathol. 2002;118:239.",Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases,Am J Clin Pathol,2002,118,,239,,,Davidson B; Dong HP; Berner A
239,"Acosta M, Pereira J, Arroz M. Screening of carcinoma metastasis by flow cytometry: a study of 238 cases. Cytometry B Clin Cytom. 2016;90:240.",Screening of carcinoma metastasis by flow cytometry: a study of 238 cases,Cytometry B Clin Cytom,2016,90,,240,,,Acosta M; Pereira J; Arroz M
240,"Tse HT, Gossett DR, Moon YS. Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping. Sci Transl Med. 2013;5:241.",Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping,Sci Transl Med,2013,5,,241,,,Tse HT; Gossett DR; Moon YS
241,"Berg KB, Churg A. GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung. Am J Surg Pathol. 2017;41:242.",GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung,Am J Surg Pathol,2017,41,,242,,,Berg KB; Churg A
242,"Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations: are we there yet?. Arch Pathol Lab Med. 2016;140:243.",New markers for separating benign from malignant mesothelial proliferations: are we there yet?,Arch Pathol Lab Med,2016,140,,243,,,Churg A; Sheffield BS; Galateau-Salle F
243,"Hwang HC, Sheffield BS, Rodriguez S. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40:244.",Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens,Am J Surg Pathol,2016,40,,244,,,Hwang HC; Sheffield BS; Rodriguez S
244,"Cigognetti M, Lonardi S, Fisogni S. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:245.",BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations,Mod Pathol,2015,28,,245,,,Cigognetti M; Lonardi S; Fisogni S
245,"Hiroshima K, Wu D, Hasegawa M. Cytologic differential diagnosis of malignant mesothelioma and reactive mesothelial cells with FISH analysis of p16. Diagn Cytopathol. 2016;44:246.",Cytologic differential diagnosis of malignant mesothelioma and reactive mesothelial cells with FISH analysis of p16,Diagn Cytopathol,2016,44,,246,,,Hiroshima K; Wu D; Hasegawa M
246,"Paintal A, Raparia K, Zakowski MF. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol. 2013;121:247.",The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey,Cancer Cytopathol,2013,121,,247,,,Paintal A; Raparia K; Zakowski MF
247,"Valente K, Blackham AU, Levine E. A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype. Am J Surg Pathol. 2016;40:248.",A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype,Am J Surg Pathol,2016,40,,248,,,Valente K; Blackham AU; Levine E
248,"Habougit C, Trombert-Paviot B, Karpathiou G. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies. Virchows Arch. 2017;470:249.",Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies,Virchows Arch,2017,470,,249,,,Habougit C; Trombert-Paviot B; Karpathiou G
249,"Kadota K, Suzuki K, Colovos C. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25:250.",A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma,Mod Pathol,2012,25,,250,,,Kadota K; Suzuki K; Colovos C
250,"Ghanim B, Klikovits T, Hoda MA. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. Br J Cancer. 2015;112:251.",Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study,Br J Cancer,2015,112,,251,,,Ghanim B; Klikovits T; Hoda MA
251,"Hatoum H, Lourdes Y, Dhillon SS. Adequacy of malignant pleural effusion for epidermal growth factor receptor mutation analysis using the pyrosequencing method. Pleura. 2015;2:252.",Adequacy of malignant pleural effusion for epidermal growth factor receptor mutation analysis using the pyrosequencing method,Pleura,2015,2,,252,,,Hatoum H; Lourdes Y; Dhillon SS
252,"Carter J, Miller JA, Feller-Kopman D. Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma the effect of preanalytical factors. Ann Am Thorac Soc. 2017;14:253.",Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma the effect of preanalytical factors,Ann Am Thorac Soc,2017,14,,253,,,Carter J; Miller JA; Feller-Kopman D
253,"Shin S, Kim J, Kim Y. Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients. Clin Chem Lab Med. 2017;55:254.",Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients,Clin Chem Lab Med,2017,55,,254,,,Shin S; Kim J; Kim Y
254,"Tang Y, Wang Z, Li Z. High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients. Proc Natl Acad Sci. 2017;114:255.",High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients,Proc Natl Acad Sci,2017,114,,255,,,Tang Y; Wang Z; Li Z
255,"Rahman NM, Ali NJ, Brown G. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65:256.",Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010,Thorax,2010,65,,256,,,Rahman NM; Ali NJ; Brown G
256,"Bibby AC, Maskell NA. Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies. Curr Opin Pulm Med. 2016;22:257.",Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies,Curr Opin Pulm Med,2016,22,,257,,,Bibby AC; Maskell NA
257,"Miyoshi S, Sasada S, Izumo T. Diagnostic utility of pleural fluid cell block versus pleural biopsy collected by flex-rigid pleuroscopy for malignant pleural disease: a single center retrospective analysis. PLoS One. 2016;11:258.",Diagnostic utility of pleural fluid cell block versus pleural biopsy collected by flex-rigid pleuroscopy for malignant pleural disease: a single center retrospective analysis,PLoS One,2016,11,,258,,,Miyoshi S; Sasada S; Izumo T
258,"Davies HE, Nicholson JE, Rahman NM. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg. 2010;38:259.",Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies,Eur J Cardiothorac Surg,2010,38,,259,,,Davies HE; Nicholson JE; Rahman NM
259,"Gunluoglu G, Olcmen A, Gunluoglu MZ. Long-term outcome of patients with undiagnosed pleural effusion. Arch Bronconeumol. 2015;51:260.",Long-term outcome of patients with undiagnosed pleural effusion,Arch Bronconeumol,2015,51,,260,,,Gunluoglu G; Olcmen A; Gunluoglu MZ
260,"Venekamp LN, Velkeniers B, Noppen M. Does 'idiopathic pleuritis' exist? Natural history of non-specific pleuritis diagnosed after thoracoscopy. Respiration. 2005;72:261.",Does 'idiopathic pleuritis' exist? Natural history of non-specific pleuritis diagnosed after thoracoscopy,Respiration,2005,72,,261,,,Venekamp LN; Velkeniers B; Noppen M
261,"Janssen JP, Ramlal S, Mravunac M. The long-term follow-up of exudative pleural effusion after nondiagnostic thoracoscopy. J Bronchol. 2004;11:262.",The long-term follow-up of exudative pleural effusion after nondiagnostic thoracoscopy,J Bronchol,2004,11,,262,,,Janssen JP; Ramlal S; Mravunac M
262,"Yang Y, Wu YB, Wang Z. Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy. Respir Med. 2017;124:263.",Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy,Respir Med,2017,124,,263,,,Yang Y; Wu YB; Wang Z
263,"Siravegna G, Marsoni S, Siena S. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:264.",Integrating liquid biopsies into the management of cancer,Nat Rev Clin Oncol,2017,14,,264,,,Siravegna G; Marsoni S; Siena S
264,"Cappellesso R, Galasso M, Nicole L. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology. Cancer. 2017;125:265.",miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology,Cancer,2017,125,,265,,,Cappellesso R; Galasso M; Nicole L
265,"Karachaliou N, Mayo-De Las Casas C, Queralt C. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol. 2015;1:266.",Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial,JAMA Oncol,2015,1,,266,,,Karachaliou N; Mayo-De Las Casas C; Queralt C
266,"Mok T, Wu YL, Lee JS. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21:267.",Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy,Clin Cancer Res,2015,21,,267,,,Mok T; Wu YL; Lee JS
267,"Oxnard GR, Thress KS, Alden RS. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:268.",Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer,J Clin Oncol,2016,34,,268,,,Oxnard GR; Thress KS; Alden RS
268,"Sacher AG, Paweletz C, Dahlberg SE. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2:269.",Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer,JAMA Oncol,2016,2,,269,,,Sacher AG; Paweletz C; Dahlberg SE
269,"Muraoka T, Soh J, Toyooka S. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer. 2013;82:270.",The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma,Lung Cancer,2013,82,,270,,,Muraoka T; Soh J; Toyooka S
270,"Santarelli L, Staffolani S, Strafella E. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer. 2015;90:271.",Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma,Lung Cancer,2015,90,,271,,,Santarelli L; Staffolani S; Strafella E
271,"Kirschner MB, Cheng YY, Badrian B. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7.",Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma,J Thorac Oncol,2012,7,,,,,Kirschner MB; Cheng YY; Badrian B
